文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA PET肿瘤与唾液腺比值预测[177Lu]PSMA放射配体治疗反应:一项国际多中心回顾性研究

PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.
PubMed 文献 · J Nucl Med · 2023-03-30

该国际多中心回顾性研究纳入237例接受[177Lu]PSMA治疗的转移性去势抵抗性前列腺癌男性,基于基线[68Ga]PSMA-11 PET建立定量和视觉PSG评分。PSG评分越高,PSA应答率越高、PSA无进展生存和总生存越好。视觉PSG评分重复性好且预后价值与定量评分相当。

要点

  • 定量PSG评分高、中、低组PSA下降超过50%的比例分别为69.6%、38.7%、16.7%(P < 0.001)。
  • 视觉PSG评分高、中、低组PSA下降超过50%的比例分别为63.2%、33.3%、16.1%(P < 0.001)。
  • 视觉PSG评分读者间重复性为Fleiss加权κ 0.68,预后价值与定量评分相当。

核心结论

  • PSG评分对[177Lu]PSMA治疗后的PSA应答和总生存具有预后价值。
  • 基于三维最大强度投影PET图像评估的视觉PSG评分重复性高,预后价值与定量评分相当。

研究设计与样本

  • 国际多中心回顾性研究,纳入237例接受[177Lu]PSMA治疗的转移性去势抵抗性前列腺癌男性。
  • 在基线[68Ga]PSMA-11 PET图像上半自动计算定量PSG评分(全身肿瘤与腮腺SUVmean比值)。
  • 按定量PSG评分分为高(> 1.5)、中(0.5-1.5)、低(< 0.5)三组。
  • 10名读者解读三维最大强度投影基线[68Ga]PSMA-11 PET图像,按视觉PSG评分分为高、中、低三组。

主要发现

  • 定量PSG评分高、中、低组分别56例(23.6%)、163例(68.8%)、18例(7.6%)。
  • 视觉PSG评分高、中、低组分别106例(44.7%)、96例(40.5%)、35例(14.8%)。
  • 视觉PSG评分读者间重复性为Fleiss加权κ 0.68。
  • 定量PSG评分高、中、低组PSA下降超过50%的比例分别为69.6%、38.7%、16.7%(P < 0.001)。
  • 视觉PSG评分高、中、低组PSA下降超过50%的比例分别为63.2%、33.3%、16.1%(P < 0.001)。

关键数值与推荐

  • 定量PSG评分分组阈值:高> 1.5,中0.5-1.5,低< 0.5。
  • 视觉PSG评分高组:多数病灶摄取高于腮腺;低组:多数病灶摄取低于腮腺;中组:介于两者之间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy can improve the outcome of patients with advanced metastatic castration-resistant prostate cancer, but patients do not respond uniformly. We hypothesized that using the salivary glands as a reference organ can enable selective patient stratification. We aimed to establish a PSMA PET tumor-to-salivary gland ratio (PSG score) to predict outcomes after [177Lu]PSMA. Methods: In total, 237 men with metastatic castration-resistant prostate cancer treated with [177Lu]PSMA were included. A quantitative PSG (qPSG) score (SUVmean ratio of whole-body tumor to parotid glands) was semiautomatically calculated on baseline [68Ga]PSMA-11 PET images. Patients were divided into 3 groups: high (qPSG > 1.5), intermediate (qPSG = 0.5-1.5), and low (qPSG < 0.5) scores. Ten readers interpreted the 3-dimensional maximum-intensity-projection baseline [68Ga]PSMA-11 PET images and classified patients into 3 groups based on visual PSG (vPSG) score: high (most of the lesions showed higher uptake than the parotid glands) intermediate (neither low nor high), and low (most of the lesions showed lower uptake than the parotid glands). Outcome data included a more than 50% prostate-specific antigen decline, prostate-specific antigen (PSA) progression-free survival, and overall survival (OS). Results: Of the 237 patients, the numbers in the high, intermediate, and low groups were 56 (23.6%), 163 (68.8%), and 18 (7.6%), respectively, for qPSG score and 106 (44.7%), 96 (40.5%), and 35 (14.8%), respectively, for vPSG score. The interreader reproducibility of the vPSG score was substantial (Fleiss weighted κ, 0.68). The more than 50% prostate-specific antigen decline was better in patients with a higher PSG score (high vs. intermediate vs. low, 69.6% vs. 38.7% vs. 16.7%, respectively, for qPSG [P < 0.001] and 63.2% vs 33.3% vs 16.1%, respectively, for vPSG [P < 0.001]). The median PSA progression-free survival of the high, intermediate, and low groups by qPSG score was 7.2, 4.0, and 1.9 mo (P < 0.001), respectively, by qPSG score and 6.7, 3.8, and 1.9 mo (P < 0.001), respectively, by vPSG score. The median OS of the high, intermediate, and low groups was 15.0, 11.2, and 13.9 mo (P = 0.017), respectively, by qPSG score and 14.3, 9.6, and 12.9 mo (P = 0.018), respectively, by vPSG score. Conclusion: The PSG score was prognostic for PSA response and OS after [177Lu]PSMA. The visual PSG score assessed on 3-dimensional maximum-intensity-projection PET images yielded substantial reproducibility and comparable prognostic value to the quantitative score.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hotta M, Gafita A, Murthy V, et al. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023. PMID: 36997329. doi:10.2967/jnumed.122.265242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。